Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Oct. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0312154/Cancer-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006–2010. During 2010–2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market.

Scope

The report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine, heated-killed yeast-based vaccine etc.

- Analysis of the current and future competition in the seven key countries cancer vaccines market. Key market players covered are Merck, NovaRx Corporation, NewLink Genetics Corporation, Bavarian Nordic, immatics biotechnologies GmbH, Oxford BioMedica, Biovex, Vaccinogen, Biovest International, Vaccinogen and GlaxoSmithKline.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the cancer vaccines market.

- Analysis of key recent licensing and partnership agreements in cancer vaccines market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global cancer vaccines market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global cancer vaccines market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global cancer vaccines market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Cancer Vaccines - Introduction 8

2.1 Overview 8

2.2 Epidemiology of Various Cancers 8

2.2.1 Cancer Incidence and Mortality in the US 8

2.2.2 Cancer Incidence and Mortality in Europe (EU5) 9

2.2.3 Cancer Incidence and Mortality in Japan. 9

2.3 Cancer Vaccines 10

2.3.1 Overview 10

2.4 Prophylactic Cancer Vaccines 14

2.4.1 Gardasil (Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant) 14

2.4.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant) 14

2.4.3 Cervical Cancer: An Introduction 15

2.5 Therapeutic Cancer Vaccines 16

2.5.1 Provenge 17

2.5.2 Prostate Cancer: An Introduction 17

2.5.3 Metastatic Prostate Cancer 18

2.6 Future of Cancer Vaccines 18

2.6.1 Drawbacks of Available Cancer Therapies 19

2.6.2 Benefits of the Upcoming Cancer Vaccines 19

2.7 GlobalData Pipeline Report Guidance 20

3 Cancer Vaccines - Market Characterization 21

3.1 Cancer Vaccines Market Size (2006-2010) – Global 21

3.2 Cancer Vaccines Market Forecast (2010-2018) – Global 22

3.3 Cancer Vaccines Market Size (2006-2010) – The US 25

3.4 Cancer Vaccines Market Forecast (2010-2018) – The US 26

3.5 Cancer Vaccines Market Size (2006-2010) – France 28

3.6 Cancer Vaccines Market Forecast (2010-2018) – France 29

3.7 Cancer Vaccines Market Size (2006-2010) – Germany 31

3.8 Cancer Vaccines Market Forecast (2010-2018) – Germany 32

3.9 Cancer Vaccines Market Size (2006-2010) – Italy 34

3.10 Cancer Vaccines Market Forecast (2010-2018) – Italy 35

3.11 Cancer Vaccines Market Size (2006-2010) – Spain 37

3.12 Cancer Vaccines Market Forecast (2010-2018) – Spain 38

3.13 Cancer Vaccines Market Size (2006-2010) – The UK 40

3.14 Cancer Vaccines Market Forecast (2010-2018) – The UK 41

3.15 Cancer Vaccines Market Size (2006-2010) – Japan 43

3.16 Cancer Vaccines Market Forecast (2010-2018) – Japan 43

3.17 Drivers and Barriers for the Cancer Vaccines Market 45

3.17.1 Drivers for the Cancer Vaccines Market 45

3.17.2 Barriers for the Cancer Vaccines Market 46

3.18 Opportunity and Unmet Need Analysis 47

3.19 Key Takeaway 48

4 Cancer Vaccines - Competitive Assessment 49

4.1 Overview 49

4.1.1 Strategic Competitor Assessment 49

4.2 Product Profiles for the Major Marketed Products in the Cancer Vaccines Therapeutics Market 50

4.2.1 Gardasil (HPV Quadrivalent (Type 6, 11, 16 and 18) Vaccine, Recombinant) 50

4.2.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant) 52

4.2.3 Provenge (sipuleucel-T) 54

4.3 Key Takeaway 55

5 Cancer Vaccines - Pipeline Assessment 56

5.1 Overview 56

5.2 Strategic Pipeline Assessment 56

5.3 Cancer Vaccines Pipeline – Pipeline by Phases of Development 57

5.3.1 Prophylactic Cancer Vaccines – Phase III Pipeline 57

5.3.2 Prophylactic Cancer Vaccines – Phase II Pipeline 58

5.3.3 Prophylactic Cancer Vaccines – Phase I/II Pipeline 58

5.3.4 Prophylactic Cancer Vaccines – Phase I Pipeline 58

5.3.5 Prophylactic Cancer Vaccines – Preclinical Pipeline 58

5.3.6 Therapeutics Cancer Vaccines– Phase III Pipeline 59

5.3.7 Therapeutics Cancer Vaccines – Phase II Pipeline 60

5.3.8 Therapeutics Cancer Vaccines – PhaseI/II Pipeline 66

5.3.9 Therapeutics Cancer Vaccines– Phase I Pipeline 71

5.3.10 Therapeutic Cancer Vaccines Market – Discovery and Pre-Clinical Pipeline 78

5.3.11 Technology Trends Analytic Framework 79

5.4 Cancer Vaccines Market – Pipeline by Mechanism of Action 82

5.5 Cancer Vaccines – Promising Drugs under Clinical Development 83

5.6 Molecule Profile for Promising Drugs Under Clinical Development (Prophylactic Cancer Vaccine) 83

5.6.1 V503 83

5.7 Molecule Profiles of Promising Drugs Under Clinical Development (Therapeutic Cancer Vaccines) 85

5.7.1 Stimuvax 85

5.7.2 OncoVAX 86

5.7.3 Oncovex (GM-CSF) 87

5.7.4 Lucanix (belagenpumatucel-L) 88

5.7.5 Trovax 89

5.7.6 HyperAcute Pancreas 89

5.7.7 Allovectin-7 90

5.7.8 IMA901 91

5.7.9 BiovaxID 91

5.7.10 MAGE-A3 ASCI 92

5.8 Key Takeaway 93

6 Cancer Vaccines - Clinical Trials Mapping 94

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 94

6.2 Clinical Trials by Phase 95

6.3 Clinical Trials by Trial Status 96

6.4 Prominent Sponsors 97

6.5 Top Companies Participating in Cancer Vaccines Clinical Trials 99

7 Cancer Vaccines - Strategic Assessment 100

7.1 Key Events Impacting the Future Market 100

7.2 Cancer Vaccines: Implications for Future Market Competition 101

8 Cancer Vaccines - Future Players 103

8.1 Introduction 103

8.2 Company Profiles 103

8.2.1 Vical Incorporated 103

8.2.2 Vaccinogen 105

8.2.3 Newlink Genetics Corporation 106

8.2.4 Biovest International (Subsidiary of Accentual Biopharmaceuticals, Inc.) 106

8.2.5 Oxford Biomedica 108

8.2.6 immatics biotechnologies GmbH 110

8.2.7 NovaRx Corporation 110

8.2.8 Oncothyreon 111

8.2.9 Other Companies in the Cancer Vaccines Market 112

9 Cancer Vaccines - Licensing and Partnership Deals 115

10 Cancer Vaccines - Appendix 133

10.1 Market Definitions 133

10.2 Abbreviations 133

10.3 Methodology 135

10.3.1 Coverage 135

10.3.2 Secondary Research 135

10.3.3 Forecasting 136

10.3.4 Primary Research 138

10.3.5 Expert Panel Validation 139

10.4 Contact Us 139

10.5 Disclaimer 139

10.6 Bibliography 140

List of Tables

Table1: Cancer Incidence and Mortality in the US, 2010 8

Table 2: Cancer Incidence and Mortality in Europe (EU5), 2010 9

Table 3: Cancer Incidence and Mortality in Japan, 2010 9

Table 4: Difference Between Autologous and Allogenic Tumor Cell Vaccines. 10

Table 5: Cancer Vaccines Market, Global, Revenue ($m), 2006–2010 22

Table 6: Cancer Vaccines Market, Global, Forecast, Revenue ($m), 2010–2018 24

Table 7: Cancer Vaccines Market, The US, Revenue ($m), 2006–2010 25

Table 8: Cancer Vaccines Market, The US, Forecasts, Revenue ($m), 2010–2018 27

Table 9: Cancer Vaccines Market, France, Revenue ($m), 2006–2010 28

Table 10: Cancer Vaccines Market, France, Forecasts, Revenue ($m), 2010–2018 30

Table 11: Cancer Vaccines Market, Germany, Revenue ($m), 2006–2010 31

Table 12: Cancer Vaccines Market, Germany, Forecasts, Revenue ($m), 2010–2018 33

Table 13: Cancer Vaccines Market, Italy, Revenue ($m), 2006–2010 34

Table 14: Cancer Vaccines Market, Italy, Forecasts, Revenue ($m), 2010–2018 36

Table 15: Cancer Vaccines Market, Spain, Revenue ($m), 2006–2010 37

Table 16: Cancer Vaccines Market, Spain, Forecast Revenue ($m), 2010–2018 39

Table 17: Cancer Vaccines Market, The UK, Revenue ($m), 2006–2010 40

Table 18: Cancer Vaccines Market, The UK, Forecasts ($m), 2010–2018 42

Table 19: Cancer Vaccines Market, Japan, Forecasts ($m), 2010–2018 44

Table 20: Gardasil Approvals and Fillings 51

Table 21: Prophylactic Cancer Vaccines– Phase III Pipeline, 2011 57

Table 22: Prophylactic Cancer Vaccines– Phase II Pipeline, 2011 58

Table 23: Prophylactic Cancer Vaccines– Phase I/II Pipeline, 2011 58

Table 24: Prophylactic Cancer Vaccines– Phase II Pipeline, 2011 58

Table 25: Prophylactic Cancer Vaccines–Preclinical Pipeline, 2011 58

Table 26: Therapeutic Cancer Vaccines– Phase III Pipeline, 2011 59

Table 27: Therapeutic Cancer Vaccines – Phase II Pipeline, 2011 60

Table 28: Therapeutic Cancer Vaccines – PhaseI/II Pipeline, 2011 66

Table 29: Therapeutic Cancer Vaccines – Phase I Pipeline, 2011 71

Table 30: Therapeutic Cancer Vaccines – Discovery and Pre-Clinical Pipeline 2011 78

Table 31: Prophylactic Cancer Vaccines – Most Promising Drugs Under Clinical Development, 2011 83

Table 32: Therapeutic Cancer Vaccines – Most Promising Drugs Under Clinical Development, 2011 84

Table 33: Cancer Vaccines – Clinical Trials by Country, 2011 94

Table 34: Cancer Vaccines - Clinical Trials by Phase, 2011 95

Table 35: Cancer Vaccines - Clinical Trials by Status, 2011 96

Table 36: Cancer Vaccines - Prominent Sponsors, 2011 98

Table 37: Cancer Vaccines - Top Companies Participating in Therapeutics Clinical Trials, 2011 99

Table 38: Vical– Cancer vaccines, Pipeline, 2011 105

Table 39: Vaccinogen- Cancer vaccines Pipeline, 2011 105

Table 40: Newlink Genetics Corporation, Cancer Vaccines Pipeline, 2011 106

Table 41: Biovest International, Cancer vaccines Pipeline, 2011 107

Table 42: Oxford BioMedica, Pipeline, 2011 109

Table 43: immatics biotechnologies , Cancer Vaccines Pipeline, 2011 110

Table 44: NovaRx Corporation,Cancer Vaccines Pipeline, 2011 110

Table 45: Oncothyreon, Cancer Vaccines Pipeline, 2011 111

Table 46: Cancer Vaccines Market – Future Players 112

Table 47: Cancer Vaccines, Global, Deals 115

List of Figures

Figure 1: Mechanism of Action of Tumor Cell Vaccine 11

Figure 2: Immunity Induction Pathway by DNA Vaccines. 13

Figure 3: Manner in which Therapeutic Cancer Vaccines are Given in Clinics 16

Figure 4: Cancer Vaccines Market, Global, Revenue ($m), 2006–2010 21

Figure 5: Prophylactic Cancer Vaccines Market, Global, Forecast ($m), 2010–2018 23

Figure 6: Therapeutic Cancer Vaccines Market, Global, Forecast ($m), 2010–2018 23

Figure 7: Cancer Vaccines Market, The US, Revenue ($m), 2006–2010 25

Figure 8: Prophylactic Cancer Vaccines Market, The US, Forecast ($m), 2010–2018 26

Figure 9: Therapeutic Cancer Vaccines Market, The US, Forecast ($m), 2010–2018 27

Figure 10: Cancer Vaccines Market, France, Revenue ($m), 2006–2010 28

Figure 11: Prophylactic Cancer Vaccines Market, France, Forecast ($m), 2010–2018 29

Figure 12: Therapeutic Cancer Vaccines Market, France, Forecast ($m), 2010–2018 30

Figure 13: Cancer Vaccines Market, Germany, Revenue ($m), 2006–2010 31

Figure 14: Prophylactic Cancer Vaccines Market, Germany, Forecast ($m), 2010–2018 32

Figure 15: Therapeutic Cancer Vaccines Market, Germany, Forecast ($m), 2010–2018 33

Figure 16: Cancer Vaccines Market, Italy, Revenue ($m), 2006–2010 34

Figure 17: Prophylactic Cancer Vaccines Market, Italy, Forecast ($m), 2010–2018 35

Figure 18: Therapeutic Cancer Vaccines Market, Italy, Forecast ($m), 2010–2018 36

Figure 19: Cancer Vaccines Market, Spain, Revenue ($m), 2006–2010 37

Figure 20: Prophylactic Cancer Vaccines Market, Spain, Forecast ($m), 2010–2018 38

Figure 21: Therapeutic Cancer Vaccines Market, Spain, Forecast ($m), 2010–2018 39

Figure 22: Cancer Vaccines Market, The UK, Revenue ($m), 2006–2010 40

Figure 23: Prophylactic Cancer Vaccines Market, The UK, Forecast ($m), 2010–2018 41

Figure 24: Therapeutic Cancer Vaccines Market, The UK, Forecast ($m), 2010–2018 42

Figure 25: Prophylactic Cancer Vaccines Market, Japan, Forecast ($m), 2010–2018 43

Figure 26: Therapeutic Cancer Vaccines Market, Japan, Forecast ($m), 2010–2018 44

Figure 27: Opportunity and Unmet Need in the Prophylactic Cancer Vaccines Market, 2011 47

Figure 28: Opportunity and Unmet Need in the Therapeutic Cancer Vaccines Market, 2011 48

Figure 29: Prophylactic Cancer Vaccines – Strategic Competitor Assessment, 2011 49

Figure 30: Therapeutic Cancer Vaccines – Strategic Competitor Assessment, 2011 50

Figure 31: Prophylactic Cancer Vaccines – Pipeline by Phases of Development, 2011 57

Figure 32: Therapeutic Cancer Vaccines – Pipeline by Phase of Development, 2011 57

Figure 33: Prophylactic Cancer Vaccines – Technology Trends Analytics Framework, 2011 79

Figure 34: Prophylactic Cancer Vaccines – Technology Trends Analytics Framework – Description, 2011 80

Figure 35: Therapeutic Cancer Vaccines– Technology Trends Analytics Framework – Description, 2011 81

Figure 36: Prophylactic Cancer Vaccines – Pipeline by Mechanism of Action, 2011 82

Figure 37: Therapeutic Cancer Vaccines – Pipeline by Mechanism of Action, 2011 83

Figure 38: Cancer Vaccines – Clinical Trials by Country, 2011 94

Figure 39: Cancer Vaccines - Clinical Trials by Phase, 2011 95

Figure 40: Cancer Vaccines - Clinical Trials by Status, 2011 96

Figure 41: Cancer Vaccines - Overall Sponsors, 2011 97

Figure 42: Cancer Vaccines - Prominent Sponsors, 2011 98

Figure 43: Cancer Vaccines - Prominent Sponsors, 2011 99

Figure 44: Cancer Vaccines Market, Drivers and Barriers ,2011 100

Figure 45: Implications for Future Market Competition in the Prophylactic Cancer Vaccines Market, 2011 101

Figure 46: Implications for Future Market Competition in the Therapeutic Cancer Vaccines Market, 2011 102

Figure 47: Cancer Vaccines Market – Pipeline by Company, 2011 103

Figure 48: GlobalData Market Forecasting Model 138

Companies Mentioned

Vical Incorporated

Vaccinogen

Newlink Genetics Corporation

Biovest International (Subsidiary of Accentual Biopharmaceuticals, Inc.)

Oxford Biomedica

immatics biotechnologies GmbH

NovaRx Corporation

Oncothyreon

To order this report:

Drug and Medication Industry: Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018

Drug and Medication Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker